Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Donald Bellgrau

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-Immunology Microbiology
Phone303/724-8733

    Collapse Research 
    Collapse research activities and funding
    R01AI022026     (BELLGRAU, DONALD)Jun 1, 1986 - May 31, 1989
    NIH/NIAID
    T-T COLLABORATION IN THE REJECTION OF ISLET ALLOGRAFTS
    Role: Principal Investigator

    R01DK048805     (BELLGRAU, DONALD)Dec 1, 1994 - Nov 30, 1998
    NIH/NIDDK
    AUTOREATIVE T CELLS RESISTANT TO TOLERANCE IN DIABETES
    Role: Principal Investigator

    R01DK058722     (BELLGRAU, DONALD)Jan 1, 2001 - Dec 31, 2005
    NIH/NIDDK
    A NOVEL T CELL ACTIVATION CONTROLLED BY A DISEASE GENE
    Role: Principal Investigator

    R43AI047618     (BELLGRAU, DONALD)Jul 1, 2001 - Dec 31, 2001
    NIH/NIAID
    USE OF FAS LIGAND TO SUPPRESS ARTHRITIS
    Role: Principal Investigator

    R43CA119840     (BELLGRAU, DONALD)Sep 30, 2006 - Aug 31, 2009
    NIH/NCI
    Provoking anti-tumor immune responses with Fas ligand
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Modiano JF, Bellgrau D. Fas ligand based immunotherapy: A potent and effective neoadjuvant with checkpoint inhibitor properties, or a systemically toxic promoter of tumor growth? Discov Med. 2016 Feb; 21(114):109-16. PMID: 27011046.
      View in: PubMed
    2. King TH, Guo Z, Hermreck M, Bellgrau D, Rodell TC. Construction and Immunogenicity Testing of Whole Recombinant Yeast-Based T-Cell Vaccines. Methods Mol Biol. 2016; 1404:529-45. PMID: 27076321.
      View in: PubMed
    3. Modiano JF, Lindborg BA, McElmurry RT, Lewellen M, Forster CL, Zamora EA, Schaack J, Bellgrau D, O'Brien TD, Tolar J. Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment. Cancer Immunol Immunother. 2015 Nov; 64(11):1449-60. PMID: 26250807; PMCID: PMC4618101 [Available on 11/01/16].
    4. King TH, Kemmler CB, Guo Z, Mann D, Lu Y, Coeshott C, Gehring AJ, Bertoletti A, Ho ZZ, Delaney W, Gaggar A, Subramanian GM, McHutchison JG, Shrivastava S, Lee YJ, Kottilil S, Bellgrau D, Rodell T, Apelian D. A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance. PLoS One. 2014; 9(7):e101904. PMID: 25051027; PMCID: PMC4106793.
    5. May SL, Zhou Q, Lewellen M, Carter CM, Coffey D, Highfill SL, Bucher CM, Matise I, Morse HC, O'Sullivan MG, Schutten M, Johnson C, Bellgrau D, Blazar BR, Modiano JF. Nfatc2 and Tob1 have non-overlapping function in T cell negative regulation and tumorigenesis. PLoS One. 2014; 9(6):e100629. PMID: 24945807; PMCID: PMC4063948.
    6. Modiano JF, Bellgrau D, Cutter GR, Lana SE, Ehrhart NP, Ehrhart E, Wilke VL, Charles JB, Munson S, Scott MC, Pozniak J, Carlson CS, Schaack J, Duke RC. Inflammation, apoptosis, and necrosis induced by neoadjuvant fas ligand gene therapy improves survival of dogs with spontaneous bone cancer. Mol Ther. 2012 Dec; 20(12):2234-43. PMID: 22850679; PMCID: PMC3519983.
    7. Tamburini BA, Kedl RM, Bellgrau D. IL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses. J Immunother. 2012 Jan; 35(1):14-22. PMID: 22130158; PMCID: PMC3241875.
    8. Tamburini BA, Phang TL, Fosmire SP, Scott MC, Trapp SC, Duckett MM, Robinson SR, Slansky JE, Sharkey LC, Cutter GR, Wojcieszyn JW, Bellgrau D, Gemmill RM, Hunter LE, Modiano JF. Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma. BMC Cancer. 2010 Nov 09; 10:619. PMID: 21062482; PMCID: PMC2994824.
    9. Jubala CM, Lamerato-Kozicki AR, Borakove M, Lang J, Gardner LA, Coffey D, Helm KM, Schaack J, Baier M, Cutter GR, Bellgrau D, Modiano JF. MHC-dependent desensitization of intrinsic anti-self reactivity. Cancer Immunol Immunother. 2009 Feb; 58(2):171-85. PMID: 18523772; PMCID: PMC2585149.
    10. Modiano JF, Johnson LD, Bellgrau D. Negative regulators in homeostasis of naïve peripheral T cells. Immunol Res. 2008; 41(2):137-53. PMID: 18415030; PMCID: PMC2587146.
    11. Haller AA, Lauer GM, King TH, Kemmler C, Fiolkoski V, Lu Y, Bellgrau D, Rodell TC, Apelian D, Franzusoff A, Duke RC. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine. 2007 Feb 09; 25(8):1452-63. PMID: 17098335.
      View in: PubMed
    12. Kupfer R, Lang J, Williams-Skipp C, Nelson M, Bellgrau D, Scheinman RI. Loss of a gimap/ian gene leads to activation of NF-kappaB through a MAPK-dependent pathway. Mol Immunol. 2007 Jan; 44(4):479-87. PMID: 16584774.
      View in: PubMed
    13. Jubala CM, Wojcieszyn JW, Valli VE, Getzy DM, Fosmire SP, Coffey D, Bellgrau D, Modiano JF. CD20 expression in normal canine B cells and in canine non-Hodgkin lymphoma. Vet Pathol. 2005 Jul; 42(4):468-76. PMID: 16006606.
      View in: PubMed
    14. Cohn A, Morse MA, O'Neil B, Bellgrau D, Duke RC, Franzusoff AJ, Munson S, Ferraro J, Rodell TC. Treatment of Ras mutation-bearing solid tumors using whole recombinant S. cerevisiae yeast expressing mutated Ras: Preliminary safety and immunogenicity results from a phase 1 trial. J Clin Oncol. 2005 Jun; 23(16_suppl):2571. PMID: 27945865.
      View in: PubMed
    15. Lang JA, Kominski D, Bellgrau D, Scheinman RI. Partial activation precedes apoptotic death in T cells harboring an IAN gene mutation. Eur J Immunol. 2004 Sep; 34(9):2396-406. PMID: 15307172.
      View in: PubMed
    16. Lu Y, Bellgrau D, Dwyer-Nield LD, Malkinson AM, Duke RC, Rodell TC, Franzusoff A. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 2004 Aug 01; 64(15):5084-8. PMID: 15289309.
      View in: PubMed
    17. Modiano JF, Sun J, Lang J, Vacano G, Patterson D, Chan D, Franzusoff A, Gianani R, Meech SJ, Duke R, Bellgrau D. Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells. Clin Immunol. 2004 Jul; 112(1):54-65. PMID: 15207782.
      View in: PubMed
    18. Frazer-Abel AA, Baksh S, Fosmire SP, Willis D, Pierce AM, Meylemans H, Linthicum DS, Burakoff SJ, Coons T, Bellgrau D, Modiano JF. Nicotine activates nuclear factor of activated T cells c2 (NFATc2) and prevents cell cycle entry in T cells. J Pharmacol Exp Ther. 2004 Nov; 311(2):758-69. PMID: 15231866.
      View in: PubMed
    19. Bellgrau D. Can getting excited over nothing provoke autoimmunity? Adv Exp Med Biol. 2004; 552:311-6. PMID: 15622971.
      View in: PubMed
    20. Lang J, Bellgrau D. Animal models of type 1 diabetes: genetics and immunological function. Adv Exp Med Biol. 2004; 552:91-116. PMID: 15622960.
      View in: PubMed
    21. Bianco SR, Sun J, Fosmire SP, Hance K, Padilla ML, Ritt MG, Getzy DM, Duke RC, Withrow SJ, Lana S, Matthiesen DT, Dow SW, Bellgrau D, Cutter GR, Helfand SC, Modiano JF. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther. 2003 Sep; 10(9):726-36. PMID: 12944992.
      View in: PubMed
    22. Zuraff-Perryman LA, Duke RC, Setser E, Nelson DP, Bellgrau D. Murine heart transgenic Fas ligand expression protects against allograft rejection. Transplant Proc. 2002 Dec; 34(8):3396-8. PMID: 12493481.
      View in: PubMed
    23. Lang J, Bellgrau D. A T-cell functional phenotype common among autoimmune-prone rodent strains. Scand J Immunol. 2002 Jun; 55(6):546-59. PMID: 12028557.
      View in: PubMed
    24. Bellgrau D, Sun J. The induction of antigen-specific graft tolerance moves a step closer to the bedside. Transplantation. 2002 May 15; 73(9):1384-5. PMID: 12023613.
      View in: PubMed
    25. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, Wilson CC. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med. 2001 May; 7(5):625-9. PMID: 11329066.
      View in: PubMed
    26. Moore JK, Scheinman RI, Bellgrau D. The identification of a novel T cell activation state controlled by a diabetogenic gene. J Immunol. 2001 Jan 01; 166(1):241-8. PMID: 11123298.
      View in: PubMed
    27. Nelson DP, Setser E, Hall DG, Schwartz SM, Hewitt T, Klevitsky R, Osinska H, Bellgrau D, Duke RC, Robbins J. Proinflammatory consequences of transgenic fas ligand expression in the heart. J Clin Invest. 2000 May; 105(9):1199-208. PMID: 10791994; PMCID: PMC378206.
    28. Moore JK, Gold DP, Dreskin SC, Lernmark A, Bellgrau D. A diabetogenic gene prevents T cells from receiving costimulatory signals. Cell Immunol. 1999 May 25; 194(1):90-7. PMID: 10357884.
      View in: PubMed
    29. Moore JK, Bellgrau D. Promiscuous activation and cell cycle entry in T cells from autoimmune animals. Transplant Proc. 1999 May; 31(3):1606-10. PMID: 10331020.
      View in: PubMed
    30. Duke RC, Newell E, Schleicher M, Meech S, Bellgrau D. Transplantation of cells and tissues expressing Fas ligand. Transplant Proc. 1999 May; 31(3):1479-81. PMID: 10330975.
      View in: PubMed
    31. Bellgrau D, Duke RC. Apoptosis and CD95 ligand in immune privileged sites. Int Rev Immunol. 1999; 18(5-6):547-62. PMID: 10672501.
      View in: PubMed
    32. Cook JL, Potter TA, Bellgrau D, Routes BA. E1A oncogene expression in target cells induces cytolytic susceptibility at a post-recognition stage in the interaction with killer lymphocytes. Oncogene. 1996 Aug 15; 13(4):833-42. PMID: 8761305.
      View in: PubMed
    33. Bellgrau D, Stenger D, Richards C, Bao F. The diabetic BB rat. Neither Th1 nor Th2? Horm Metab Res. 1996 Jun; 28(6):299-301. PMID: 8811334.
      View in: PubMed
    34. Sellins KS, Gold DP, Bellgrau D. Resistance to tolerance induction in the diabetes-prone biobreeding rat as one manifestation of abnormal responses to superantigens. Diabetologia. 1996 Jan; 39(1):28-36. PMID: 8720600.
      View in: PubMed
    35. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke RC. A role for CD95 ligand in preventing graft rejection. Nature. 1995 Oct 19; 377(6550):630-2. PMID: 7566174.
      View in: PubMed
    36. Gold DP, Shaikewitz ST, Mueller D, Redd JR, Sellins KS, Pettersson A, Lernmark A, Bellgrau D. T cells from BB-DP rats show a unique cytokine mRNA profile associated with the IDDM1 susceptibility gene, Lyp. Autoimmunity. 1995; 22(3):149-61. PMID: 8734569.
      View in: PubMed
    37. Fleshner M, Bellgrau D, Watkins LR, Laudenslager ML, Maier SF. Stress-induced reduction in the rat mixed lymphocyte reaction is due to macrophages and not to changes in T cell phenotypes. J Neuroimmunol. 1995 Jan; 56(1):45-52. PMID: 7822481.
      View in: PubMed
    38. Kruse CA, Schiltz PM, Bellgrau D, Kong Q, Kleinschmidt-DeMasters BK. Intracranial administrations of single or multiple source allogeneic cytotoxic T lymphocytes: chronic therapy for primary brain tumors. J Neurooncol. 1994; 19(2):161-8. PMID: 7964992.
      View in: PubMed
    39. Bellgrau D, Redd JM, Sellins KS. Peculiar T-cell signaling does not preclude positive selection in the diabetes-prone BB rat. Diabetes. 1994 Jan; 43(1):47-52. PMID: 8262316.
      View in: PubMed
    40. Kruse CA, Mitchell DH, Kleinschmidt-DeMasters BK, Bellgrau D, Eule JM, Parra JR, Kong Q, Lillehei KO. Systemic chemotherapy combined with local adoptive immunotherapy cures rats bearing 9L gliosarcoma. J Neurooncol. 1993 Feb; 15(2):97-112. PMID: 8509824.
      View in: PubMed
    41. Fleshner M, Watkins LR, Lockwood LL, Bellgrau D, Laudenslager ML, Maier SF. Specific changes in lymphocyte subpopulations: a potential mechanism for stress-induced immunomodulation. J Neuroimmunol. 1992 Dec; 41(2):131-42. PMID: 1469075.
      View in: PubMed
    42. Sellins KS, Bellgrau D, Gold DP. Specificity of rat T cell receptor V beta chain usage in proliferative responses to staphylococcal enterotoxin B. Eur J Immunol. 1992 Jul; 22(7):1931-4. PMID: 1385576.
      View in: PubMed
    43. Fleshner M, Watkins LR, Redd JM, Kruse CA, Bellgrau D. A 9L gliosarcoma transplantation model for studying adoptive immunotherapy into the brains of conscious rats. Cell Transplant. 1992; 1(4):307-12. PMID: 1344303.
      View in: PubMed
    44. Redd JM, Lagarde AC, Kruse CA, Bellgrau D. Allogeneic tumor-specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 1992; 34(5):349-54. PMID: 1371720.
      View in: PubMed
    45. Gold DP, Bellgrau D. Identification of a limited T-cell receptor beta chain variable region repertoire associated with diabetes in the BB rat. Proc Natl Acad Sci U S A. 1991 Nov 01; 88(21):9888-91. PMID: 1658791; PMCID: PMC52826.
    46. Routes JM, Bellgrau D, McGrory WJ, Bautista DS, Graham FL, Cook JL. Anti-adenovirus type 5 cytotoxic T lymphocytes: immunodominant epitopes are encoded by the E1A gene. J Virol. 1991 Mar; 65(3):1450-7. PMID: 1704928; PMCID: PMC239925.
    47. Kruse CA, Lillehei KO, Mitchell DH, Kleinschmidt-DeMasters B, Bellgrau D. Analysis of interleukin 2 and various effector cell populations in adoptive immunotherapy of 9L rat gliosarcoma: allogeneic cytotoxic T lymphocytes prevent tumor take. Proc Natl Acad Sci U S A. 1990 Dec; 87(24):9577-81. PMID: 2263613; PMCID: PMC55215.
    48. Bellgrau D, Selawry HP. Cyclosporine-induced tolerance to intratesticular islet xenografts. Transplantation. 1990 Oct; 50(4):654-7. PMID: 2219288.
      View in: PubMed
    49. Babcock SK, Niswender K, Wilson DB, Bellgrau D. Cyclosporine-induced autoimmunity in rats carrying thymus allografts. Transplantation. 1990 Aug; 50(2):278-81. PMID: 2382294.
      View in: PubMed
    50. Bellgrau D, Lagarde AC. Cytotoxic T-cell precursors with low-level CD8 in the diabetes-prone Biobreeding rat: implications for generation of an autoimmune T-cell repertoire. Proc Natl Acad Sci U S A. 1990 Jan; 87(1):313-7. PMID: 2104982; PMCID: PMC53253.
    51. Georgiou HM, Bellgrau D. Persistent immunogenicity of rat thymic epithelium. Transplantation. 1989 Aug; 48(2):302-6. PMID: 2526972.
      View in: PubMed
    52. Georgiou HM, Bellgrau D. Thymus transplantation and disease prevention in the diabetes-prone Bio-Breeding rat. J Immunol. 1989 May 15; 142(10):3400-5. PMID: 2654288.
      View in: PubMed
    53. Georgiou HM, Bellgrau D. Modulation of insulitis following thymus transplantation. Transplant Proc. 1989 Feb; 21(1 Pt 1):215-7. PMID: 2650106.
      View in: PubMed
    54. Selawry HP, Whittington KB, Bellgrau D. Abdominal intratesticular islet-xenograft survival in rats. Diabetes. 1989 Jan; 38 Suppl 1:220-3. PMID: 2492008.
      View in: PubMed
    55. Mely-Goubert B, Bellgrau D, Gerson DF. Cell surface energy and membrane associated actin in lymphocytes. Cell Biophys. 1988 Aug; 13(1):65-73. PMID: 2456153.
      View in: PubMed
    56. McAteer MJ, Lagarde AC, Georgiou HM, Bellgrau D. A requirement for the CD5 antigen in T cell activation. Eur J Immunol. 1988 Jul; 18(7):1111-7. PMID: 2456937.
      View in: PubMed
    57. Bellgrau D, Walker TA, Cook JL. Recognition of adenovirus E1A gene products on immortalized cell surfaces by cytotoxic T lymphocytes. J Virol. 1988 May; 62(5):1513-9. PMID: 2451753; PMCID: PMC253175.
    58. Georgiou HM, Lagarde AC, Bellgrau D. T cell dysfunction in the diabetes-prone BB rat. A role for thymic migrants that are not T cell precursors. J Exp Med. 1988 Jan 01; 167(1):132-48. PMID: 2961842; PMCID: PMC2188817.
    59. Haug CE, Gill RG, Babcock SK, Lafferty KJ, Bellgrau D, Weil R. Cyclosporine-induced tolerance requires antigens capable of initiating an immune response. J Immunol. 1987 Nov 01; 139(9):2947-9. PMID: 3117881.
      View in: PubMed
    60. Babcock SK, Gill RG, Bellgrau D, Lafferty KJ. Studies on the two-signal model for T cell activation in vivo. Transplant Proc. 1987 Feb; 19(1 Pt 1):303-6. PMID: 3103279.
      View in: PubMed
    61. Bellgrau D, Hawkins G, Babcock S, Prowse S. Separation of T cell subsets following the injection of UV-irradiated alloantigen in vivo; failure of the lymphokine-dependent subset to reject cultured islet allografts. Transplant Proc. 1987 Feb; 19(1 Pt 1):310-2. PMID: 3152702.
      View in: PubMed
    62. Bellgrau D, Talmage DW. T cells can be cytotoxic without making interleukin 2: a model of separate pathways of induction. Proc Natl Acad Sci U S A. 1986 May; 83(10):3412-6. PMID: 2939451; PMCID: PMC323524.
    63. Prowse SJ, Bellgrau D, Lafferty KJ. Pathogenesis of spontaneous diabetes in the BB rat: is there a role for antibody? Transplant Proc. 1986 Apr; 18(2):313-5. PMID: 3083545.
      View in: PubMed
    64. Prowse SJ, Bellgrau D, Lafferty KJ. Islet allografts are destroyed by disease occurrence in the spontaneously diabetic BB rat. Diabetes. 1986 Jan; 35(1):110-4. PMID: 3079713.
      View in: PubMed
    65. Hodgkin PD, Agostino M, Sellins K, Prowse SJ, Bellgrau D, Lafferty KJ. T lymphocyte function in vivo. Ambivalence of the class I MHC antigen-reactive subset. Transplantation. 1985 Sep; 40(3):288-92. PMID: 3929437.
      View in: PubMed
    66. Bellgrau D, Lagarde AC. In vivo separation of two classes of T cells as determined by negative selection after the injection of UV-treated allogeneic lymphoid cells. Proc Natl Acad Sci U S A. 1985 Aug; 82(15):5136-9. PMID: 3875095; PMCID: PMC390514.
    67. Mély-Goubert B, Matzku S, Bellgrau D. DNase I inhibitions in tumors of different metastasizing capacities: a possible index of invasiveness. Cancer Biochem Biophys. 1983 Dec; 7(1):39-44. PMID: 6230149.
      View in: PubMed
    68. Kämpe O, Bellgrau D, Hammerling U, Lind P, Pääbo S, Severinsson L, Peterson PA. Complex formation of class I transplantation antigens and a viral glycoprotein. J Biol Chem. 1983 Sep 10; 258(17):10594-8. PMID: 6885796.
      View in: PubMed
    69. Naji A, Silvers WK, Kimura H, Bellgrau D, Markmann JF, Barker CF. Analytical and functional studies on the T cells of untreated and immunologically tolerant diabetes-prone BB rats. J Immunol. 1983 May; 130(5):2168-72. PMID: 6220083.
      View in: PubMed
    70. Bellgrau D, Zöller M. Cytotoxic T lymphocyte responses to spontaneous tumors: immunogenicity dependent on the recognition of processed tumor antigens. J Immunol. 1983 May; 130(5):2005-7. PMID: 6403615.
      View in: PubMed
    71. Bellgrau D. Induction of cytotoxic T cell precursors in vivo. Role of T helper cells. J Exp Med. 1983 May 01; 157(5):1505-15. PMID: 6222131; PMCID: PMC2187017.
    72. Bellgrau D, Naji A, Silvers WK, Markmann JF, Barker CF. Spontaneous diabetes in BB rats: evidence for a T cell dependent immune response defect. Diabetologia. 1982 Oct; 23(4):359-64. PMID: 6216134.
      View in: PubMed
    73. Naji A, Bellgrau D, Anderson A, Silvers WK, Barker CF. Transplantation of islets and bone marrow cells to animals with immune insulitis. Diabetes. 1982 Aug; 31 Suppl 4:84-91. PMID: 6819968.
      View in: PubMed
    74. Zöller M, Bellgrau D, Axberg I, Wigzell H. Natural killer cells do not belong to the recirculating lymphocyte population. Scand J Immunol. 1982 Feb; 15(2):159-67. PMID: 6179152.
      View in: PubMed
    75. Bellgrau D, Smilek D, Wilson DB. Specific systemic graft-versus-host resistance: failure to induce in adult F1 rats tolerized at birth to anti-MHC receptors on parental T cells. Adv Exp Med Biol. 1982; 149:563-7. PMID: 6983230.
      View in: PubMed
    76. Naji A, Silvers WK, Bellgrau D, Barker CF. Spontaneous diabetes in rats: destruction of islets is prevented by immunological tolerance. Science. 1981 Sep 18; 213(4514):1390-2. PMID: 6791286.
      View in: PubMed
    77. Silvers WK, Bellgrau D, Anderson AO, Plotkin S, Barker CF. Prevention of diabetes in rats by bone marrow transplantation. Ann Surg. 1981 Sep; 194(3):328-38. PMID: 6791599; PMCID: PMC1345362.
    78. Mely-Goubert B, Bellgrau D. Actin content in lymphocytes: a proposed correlation with their recirculating properties. J Immunol. 1981 Aug; 127(2):399-401. PMID: 6972959.
      View in: PubMed
    79. Bellgrau D, Smilek D, Wilson DB. Induced tolerance in F1 rats to anti-major histocompatibility complex receptors on parental T cells. Implications for self tolerance. J Exp Med. 1981 Jun 01; 153(6):1660-5. PMID: 6973003; PMCID: PMC2186183.
    80. Bellgrau D, Wilson DB. Immunological studies of T-cell receptors. II. Limited polymorphism of idiotypic determinants on T-cell receptors specific for major histocompatibility complex alloantigens. J Exp Med. 1979 Jan 01; 149(1):234-43. PMID: 33224; PMCID: PMC2184750.
    81. Bellgrau D, Wilson DB. Immunological studies of T-cell receptors. I. Specifically induced resistance to graft-versus-host disease in rats mediated by host T-cell immunity to alloreactive parental T cells. J Exp Med. 1978 Jul 01; 148(1):103-14. PMID: 78954; PMCID: PMC2184917.
    Bellgrau's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _

    Copyright © 2017 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.10.0)